Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and infants: two clinical trials

Xavier Sáez-Llorens, Ananda S Bandyopadhyay, Christopher Gast, Tirza De Leon, Rodrigo DeAntonio, Jose Jimeno, Maria Isabel Caballero, Gabriela Aguirre, M Steven Oberste, William C Weldon, Jennifer L Konopka-Anstadt, John Modlin, Novilia S Bachtiar, Alan Fix, John Konz, Ralf Clemens, Sue Ann Costa Clemens, Ricardo Rüttimann, Xavier Sáez-Llorens, Ananda S Bandyopadhyay, Christopher Gast, Tirza De Leon, Rodrigo DeAntonio, Jose Jimeno, Maria Isabel Caballero, Gabriela Aguirre, M Steven Oberste, William C Weldon, Jennifer L Konopka-Anstadt, John Modlin, Novilia S Bachtiar, Alan Fix, John Konz, Ralf Clemens, Sue Ann Costa Clemens, Ricardo Rüttimann

Abstract

Background: Continued emergence and spread of circulating vaccine-derived type 2 polioviruses and vaccine-associated paralytic poliomyelitis from Sabin oral poliovirus vaccines (OPVs) has stimulated development of two novel type 2 OPV candidates (OPV2-c1 and OPV2-c2) designed to have similar immunogenicity, improved genetic stability, and less potential to reacquire neurovirulence. We aimed to assess safety and immunogenicity of the two novel OPV candidates compared with a monovalent Sabin OPV in children and infants.

Methods: We did two single-centre, multi-site, partly-masked, randomised trials in healthy cohorts of children (aged 1-4 years) and infants (aged 18-22 weeks) in Panama: a control phase 4 study with monovalent Sabin OPV2 before global cessation of monovalent OPV2 use, and a phase 2 study with low and high doses of two novel OPV2 candidates. All participants received one OPV2 vaccination and subsets received two doses 28 days apart. Parents reported solicited and unsolicited adverse events. Type 2 poliovirus neutralising antibodies were measured at days 0, 7, 28, and 56, and stool viral shedding was assessed up to 28 days post-vaccination. Primary objectives were to assess safety in all participants and non-inferiority of novel OPV2 day 28 seroprotection versus monovalent OPV2 in infants (non-inferiority margin 10%). These studies were registered with ClinicalTrials.gov, NCT02521974 and NCT03554798.

Findings: The control study took place between Oct 23, 2015, and April 29, 2016, and the subsequent phase 2 study between Sept 19, 2018, and Sept 30, 2019. 150 children (50 in the control study and 100 of 129 assessed for eligibility in the novel OPV2 study) and 684 infants (110 of 114 assessed for eligibility in the control study and 574 of 684 assessed for eligibility in the novel OPV2 study) were enrolled and received at least one study vaccination. Vaccinations were safe and well tolerated with no causally associated serious adverse events or important medical events in any group. Solicited and unsolicited adverse events were overwhelmingly mild or moderate irrespective of vaccine or dose. Nearly all children were seroprotected at baseline, indicating high baseline immunity. In children, the seroprotection rate 28 days after one dose was 100% for monovalent OPV2 and both novel OPV2 candidates. In infants at day 28, 91 (94% [95% CI 87-98]) of 97 were seroprotected after receiving monovalent OPV2, 134 (94% [88-97]) of 143 after high-dose novel OPV2-c1, 122 (93% [87-97]) of 131 after low-dose novel OPV2-c1, 138 (95% [90-98]) of 146 after high-dose novel OPV2-c2, and 115 (91% [84-95]) of 127 after low-dose novel OPV2-c2. Non-inferiority was shown for low-dose and high-dose novel OPV2-c1 and high-dose novel OPV2-c2 despite monovalent OPV2 recipients having higher baseline immunity.

Interpretation: Both novel OPV2 candidates were safe, well tolerated, and immunogenic in children and infants. Novel OPV2 could be an important addition to our resources against poliovirus given the current epidemiological situation.

Funding: Fighting Infectious Diseases in Emerging Countries and Bill & Melinda Gates Foundation.

Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.

Figures

Figure 1
Figure 1
Trial profiles Per-protocol set used for immunogenicity analyses at day 28, and those additionally analysed at day 56 after two doses. OPV2=type 2 oral poliovirus vaccine.
Figure 2
Figure 2
Type 2 shedding in children and infants after monovalent OPV2 and high-dose novel OPV2 administration Proportions (with 95% CI) of children (A) and infants (B) shedding poliovirus type 2 (PCR-positive stools) 7, 14, 21, and 28 days after vaccination with monovalent OPV2 or high-dose novel OPV2 candidates. Shedding was compared with the two-sided Fisher's exact test. p values indicated when novel OPV2 data were significantly different versus monovalent OPV2. OPV2=type 2 oral poliovirus vaccine.

References

    1. WHO Two out of three wild poliovirus strains eradicated. 2019.
    1. Global Polio Eradication Initiative Polio this week as of 03 December 2020. 2020.
    1. WHO Meeting of the strategic advisory group of experts on immunization, 31 March–1 April 2020: conclusions and recommendations: polio. Wkly Epidemiol Rec. 2020;22:249–252.
    1. Kalkowska DA, Pallansch MA, Wilkinson A. Updated characterization of outbreak response strategies for 2019–2029: impacts of using a novel type 2 oral poliovirus vaccine strain. Risk Anal. 2020 doi: 10.1111/risa.13622. published online Nov 10.
    1. Burns CC, Diop OM, Sutter RW, Kew OM. Vaccine-derived polioviruses. J Infect Dis. 2014;210(suppl 1):S283–S293.
    1. Alleman MM, Jorba J, Greene SA. Update on vaccine-derived poliovirus outbreaks - worldwide, July 2019–February 2020. MMWR Morb Mortal Wkly Rep. 2020;69:489–495.
    1. WHO Statement of the twenty-sixth polio IHR emergency committee. Oct 22, 2020.
    1. Hampton LM, Farrell M, Ramirez-Gonzalez A. Cessation of trivalent oral poliovirus vaccine and introduction of inactivated poliovirus vaccine—worldwide, 2016. MMWR Morb Mortal Wkly Rep. 2016;65:934–938.
    1. Bandyopadhyay AS, Gast C, Brickley EB. A randomized phase 4 study of immunogenicity and safety following monovalent oral type 2 Sabin polio vaccine challenge in IPV-vaccinated children in Lithuania. J Infect Dis. 2020 doi: 10.1093/infdis/jiaa390. published online July 4.
    1. WHO–Global Polio Eradication Initiative . World Health Organization; Geneva: 2020. Strategy for the response to type 2 circulating vaccine-derived poliovirus 2020–2021: an addendum to the Polio Endgame Strategy 2019–2023.
    1. Konopka-Anstadt JL, Campagnoli R, Vincent A. Development of a new oral poliovirus vaccine for the eradication end game using codon deoptimization. NPJ Vaccines. 2020;5:26.
    1. Yeh MT, Bujaki E, Dolan PT. Engineering the live-attenuated polio vaccine to prevent reversion to virulence. Cell Host Microbe. 2020;27:736. 51.e8.
    1. Van Damme P, De Coster I, Bandyopadhyay AS. The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study. Lancet. 2019;394:148–158.
    1. De Coster I, Leroux-Roels I, Bandyopadhyay AS. Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials. Lancet. 2020 doi: 10.1016/S0140-6736(20)32541-1. published online Dec 9.
    1. Weldon WC, Oberste MS, Pallansch MA. Standardized methods for detection of poliovirus antibodies. In: Martín J, editor. Poliovirus: methods in molecular biology. Humana Press; New York: 2016. pp. 145–176.
    1. US Department of Health and Human Services Common terminology criteria for adverse events (CTCAE 4.03, June 14, 2010) 2010.
    1. Macklin GR, O'Reilly KM, Grassly NC. Evolving epidemiology of poliovirus serotype 2 following withdrawal of the serotype 2 oral poliovirus vaccine. Science. 2020;368:401–405.
    1. O'Ryan M, Bandyopadhyay AS, Villena R. Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open-label, phase 4, non-inferiority study. Lancet Infect Dis. 2015;15:1273–1282.
    1. Asturias EJ, Bandyopadhyay AS, Self S. Humoral and intestinal immunity induced by new schedules of bivalent oral poliovirus vaccine and one or two doses of inactivated poliovirus vaccine in Latin American infants: an open-label randomised controlled trial. Lancet. 2016;388:158–169.
    1. WHO First ever vaccine listed under WHO emergency use, 13 November 2020. 2020.
    1. Irwin A. News: new polio vaccine poised to get emergency WHO approval. Oct 29, 2020.
    1. Roberts L. The polio eradication campaign is faltering. Can a new vaccine help it get back on track? Nov 10, 2020.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться